<DOC>
	<DOCNO>NCT02064192</DOCNO>
	<brief_summary>The `` EUropean Comparative Effectiveness Research ass use primary prophylacTic Implantable Cardioverter Defibrillators ( EU-CERT-ICD ) '' modular research project study effectiveness prophylactic ICDs prospective study , retrospective registry , meta-analyses exist evidence subject .</brief_summary>
	<brief_title>Comparative Effectiveness Research Assess Use Primary ProphylacTic Implantable Cardioverter Defibrillators Europe</brief_title>
	<detailed_description>The prospective study part observational , prospective multi-centre study aim enrol 2500 patient ischemic dilate cardiomyopathy primary prophylactic ICD indication reduce leave ventricular ejection fraction ( LVEF ) accord current guideline . According treat physician 's decision preference independent study participation , patient recruit one two group : patient directly prior first ICD implantation ( ICD Group ) , patient consider prophylactic ICD treatment physician consider refuse ICD treatment ( Control Group ) . Patients undergo simple 12-lead electrocardiogram ( ECG ) Holter ECG diagnostics baseline well genetic biobanking entry study . All patient subsequently follow least 1 year 4 year . Co-primary endpoint all-cause mortality appropriate ICD shock .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>Ischemic dilate cardiomyopathy recommendation primary prophylactic ICD treatment follow current international treatment guideline Written inform consent If ICD implantation plan , enrollment study baseline test need complete denovo ICD implantation Permanent atrial fibrillation atrial fibrillation baseline case 15 % patient give time enrol Indication secondary prophylactic ICD treatment Indication candidate cardiac resynchronization therapy AV block II°III° rest heart rate Implanted pacemaker Unstable cardiac disease decompensated heart failure ( NYHA functional class IV ) acute coronary syndrome Participation clinical trial exclude enrolment trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>defibrillator , implantable cardioverter</keyword>
	<keyword>sudden cardiac death</keyword>
	<keyword>primary prophylaxis</keyword>
	<keyword>risk stratification</keyword>
</DOC>